NovoCure (NVCR) Non-Current Deferred Tax Liability (2018)

NovoCure's (NVCR) quarterly Non-Current Deferred Tax Liability came in at $124000.0 in Q4 2018.

NovoCure (NVCR) Non-Current Deferred Tax Liability (2018) Analysis & Trends

NovoCure has disclosed Non-Current Deferred Tax Liability across 1 years of filings, most recently posting $124000.0 for Q4 2018.

Non-Current Deferred Tax Liability for Q4 2018 came in at $124000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $124000.0 (changed N/A YoY), and the FY2018 annual result was $124000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability came in at $124000.0 for Q4 2018 at NovoCure.
In the past five years, Non-Current Deferred Tax Liability ranged from a high of $124000.0 in Q4 2018 to a low of $124000.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	NovoCure	1.63 Bn	1.20 Bn	135.13 Mn

Download Data

Date	Value
Dec 31, 2018	124,000.00
Dec 31, 2018	124,000.00